 BEDMER, N.J.--BUSINESS WIRE--- TYME--Tyme Technologies, Inc. NASDAQ: TYME, an emerging biotechnology company developing cancer metabolism-based therapies CMBTsTM, announced that, effective November 24, 2020, Steve Hoffman will remain in the role of Chairman of the board of directors and continue as the Companys Chief Science Officer, after a successful tenure as Chief Executive Officer since 2015. Richie Cunningham, former Icagen CEO and Boehringer Ingelheim executive, has been appointed as 